Analysis of related factors for long-term results and prognosis of personalized treatment in T790M-positive lung adenocarcinoma patients with bone metastasis
10.3872/j.issn.1007-385x.2019.02.010
- VernacularTitle:T790M基因突变阳性的肺腺癌并骨转移患者个体化治疗远期疗效及预 后的相关因素分析
- Author:
CHEN Long
1
,
2
;
WANG Lin
3
;
HE Donglei
4
;
LIANG Dong
1
,
2
;
FENG Jun
1
,
2
Author Information
1. Department of Oncology, the Third People&rsquo
2. s Hospital of Hainan Province,
3. DepartmentofOncology,HainanGeneralHospital
4. .DepartmentofGastrointestinalCancerSurgery, The FirstAffiliated Hospital of Hainan Medical College
- Publication Type:Journal Article
- Keywords:
lung adenocarcinoma;
T790M gene;
KRAS gene;
bone metastasis;
osimertinib;
prognosis
- From:
Chinese Journal of Cancer Biotherapy
2019;26(2):200-205
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the related factors for efficacy and prognosis of personalized comprehensive treatment for T790Mpositive lung adenocarcinoma patients with bone metastasis. Methods: The clinical data of 68 patients undergoing personalized comprehensive treatment for T790M-positive lung adenocarcinoma with bone metastasis were retrospectively reviewed; chemotherapy, radiotherapy, molecule-targeted agents, Bevacizumab, bisphosphonate and other therapies were chosen for the patients, and the efficacy and prognosis were observed to explore the related factors. Results: Effective rate of personalized comprehensive treatment was 60.3% (41/ 68), with a median survival time of 23 months. Multiple factors showed significant effects on long-term efficacy, such as no radiotherapy, T790M mutation but no KRAS mutation, adjuvant scheme+rescue scheme in prior chemotherapy treatment, N1 stage, isolated bone metastasis, alternative treatment of osimertinib with chemotherapy, less metastasized organs and ECOG scores<2 (P<0.05). Multivariate analysis revealed that T790M mutation but no KRAS mutation (P=0.012), number of metastasized organs =0 or 1 (P=0.000), alternative treatment of osimertinib with chemotherapy (P=0.020), and isolated bone metastasis (P=0.006) were independent protective factors for long-term results of personalized comprehensive treatment for T790M-positive lung adenocarcinoma patients with bone metastasis. Conclusion: Chemotherapy combined with osimertinib, agents of bisphosphonate and other personalized comprehensive treatment prolongs survival time in T790M-positive lung adenocarcinoma patients without KRAS mutation, providing a potential therapeutic model for those patients.
- Full text:20190210.pdf
